

Listing of the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-61. (CANCELED)

62. (Previously presented) A method for treating or preventing a viral infection comprising administering to an individual who has a viral infection or is at risk of being infected a formulation comprising one or more siRNAs directed against CCR5 sequence and a pharmaceutically acceptable carrier.

63. (Previously presented) The method of claim 62, wherein the infection is selected from the group consisting of: HIV, poliovirus, influenza, rhinovirus, Ebola virus, foot and mouth virus, papilloma virus infection, hepatitis, human papilloma virus (HPV), and herpes (HSV-2).

64. (Previously presented) The method of claim 62, wherein the formulation comprises an siRNA selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and a combination thereof.

65. (Previously presented) The method of claim 63, wherein the formulation further comprises one or more siRNAs directed against HIV p24 sequence.

66. (Previously presented) The method of claim 65, wherein the formulation comprises siRNAs selected from the SEQ ID NO: 1 and SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 and combinations thereof.

67. (Previously presented) The method of claim 62, wherein the pharmaceutically acceptable carrier comprises a component selected from the group consisting of a basic peptide, nonoxynol-9-containing spermicide, vaginal lubricant, liposomes, and combinations thereof.

68. (Previously presented) The method of claim 67, wherein the peptide is selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31.

69. (Previously presented) The method of claim 62, wherein the administering is performed topically.
70. (Previously presented) The method of claim 62, wherein the administering is performed intravaginally.
71. (Previously presented) A microbicide comprising an siRNAs directed against CCR5 transcript and a pharmaceutically acceptable carrier.
72. (Previously presented) The microbicide of claim 71, wherein the siRNA is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and combinations thereof.
73. (Previously presented) The microbicide according to claim 71, further comprising an siRNAs directed against HIV p24 sequence
74. (Previously presented) The microbicide according to claim 73, wherein the siRNAs comprise siRNAs selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and combinations thereof.
75. (Previously presented) The microbicide of claim 74, wherein the pharmaceutically acceptable carrier comprises a component selected from the group consisting of a basic peptide, nonoxynol-9-containing spermicide, vaginal lubricant, liposomes, and combinations thereof.
76. (Previously presented) The microbicide of claim 75, wherein the basic peptide is selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, and SEQ ID NO: 31.